RecruitingPhase 1NCT07070882

Oral Steroid Taper After Total Knee Arthroplasty

Effectiveness of an Oral Methylprednisolone Taper Following Primary Total Knee Arthroplasty


Sponsor

Columbia University

Enrollment

130 participants

Start Date

Jun 20, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

This study aims to evaluate the effectiveness of an oral methylprednisolone taper in reducing postoperative pain, opioid consumption, and nausea following primary total knee arthroplasty (TKA).


Eligibility

Min Age: 18 Years

Inclusion Criteria4

  • Any patient undergoing primary TKA with a diagnosis of osteoarthritis
  • > 18 years old
  • Willingness to undergo randomization
  • Patients who will be home by postoperative day (POD) #1 to start the dosing schedule that day (includes both ambulatory and POD #1 discharge patients)

Exclusion Criteria14

  • Reported chronic corticosteroid or opiate use prior to surgery
  • Prior Open Surgery on the Ipsilateral Knee
  • Primary diagnosis other than osteoarthritis, including avascular necrosis, fracture, septic arthritis, or postoperative traumatic arthritis
  • American Society of Anesthesiologists (ASA) score ≥ 4
  • Reported history of liver disease, renal disease, or diabetes mellitus
  • Current systemic fungal infection or other local infection
  • Immunocompromised or immunosuppressed
  • Current peptic ulcer disease
  • History of psychosis, heart failure, myasthenia gravis, ocular herpes simplex virus, or systemic sclerosis
  • Women with reported current pregnancy
  • Known hypersensitivity to methylprednisolone
  • ≤ 18 years old
  • Inability to take oral medications
  • Unable to provide consent

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMethylprednisolone

Patients will receive a tapered dose of methylprednisolone with the standard of care pain management


Locations(1)

Columbia University Medical Center

New York, New York, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07070882


Related Trials